ReviewClinical ophthalmology (Auckland, N.Z.)2026
Rates of Drug-Induced Uveitis: A Review by Medication Class.
Review in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Drug-induced uveitis is an uncommon but clinically important cause of intraocular inflammation across diverse systemic and ophthalmic therapies. As the use of biologics, targeted agents, and chronic ocular medications expands, clinicians need drug class-specific data on risk, phenotype, and clinical course. In this study, we synthesize and review the published literature on drug-induced uveitis, summarizing reported incidence, clinical phenotypes, latency to onset, and time to resolution by medication class, route of administration, and patient-level factors. Methods: A systematic literature search was conducted with PubMed, Scopus, and the Cochrane Library in September 2025 using terms related to drug-induced and medication-associated uveitis. Articles were included if they discussed human cases of noninfectious uveitis attributed to a specific medication or drug class and were written in English. Data analysis was performed to assess relationships between medication class, medication exposure time, uveitis location, uveitis treatment, and uveitis resolution time. Results: 317 articles with 690 unique patient cases met inclusion criteria for case-level data analysis. The mean age at drug-induced uveitis onset was 54.4 years; most patients were female, 63.4% had bilateral disease, and 74.8% had anterior uveitis. Mean exposure time from first dose to uveitis onset was 197.2 days (SD 497.6; range, 0-6205), and mean resolution time was 61.0 days (SD 157.4; range, 1-2520). Antineoplastics (29.1%), vaccines (15.8%), antibiotics (13.0%), intraocular pressure-lowering drops (11.9%), bisphosphonates (9.7%), vascular endothelial growth factor (VEGF) inhibitors (6.4%), antivirals (5.1%), and disease-modifying antirheumatic drugs (4.3%) were the most frequently implicated classes. Conclusion: Drug-induced uveitis, although rare, represents a broad array of presentations, mechanisms, and clinical course. As systemic and targeted therapeutic use continues to expand, understanding the clinical presenation and course will help patient outcomes and minimize vision-threatening risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.